Skip to main content
Minerva Neurosciences, Inc. logo

Minerva Neurosciences, Inc. — Investor Relations & Filings

Ticker · NERV ISIN · US6033802058 LEI · 54930017PANCHC5LYH79 US Manufacturing
Open in API
Filings indexed 589 across all filing types
Latest filing 2017-02-03 Major Shareholding Noti…
Country US United States of America
Listing US NERV

About Minerva Neurosciences, Inc.

https://www.minervaneurosciences.com/

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of product candidates for the treatment of central nervous system (CNS) diseases. The company's lead product candidate is roluperidone, which is being developed to treat the negative symptoms of schizophrenia. Minerva Neurosciences leverages its expertise in clinical development to design innovative trials with clinical endpoints aimed at demonstrating direct patient benefit.

Recent filings

Filing Released Lang Actions
AMENDMENT NO. 2
Major Shareholding Notification
2017-02-03 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K, which is a current report filed with the SEC to announce unscheduled material events or corporate changes. The text mentions the filing of a press release and a corporate presentation slide as exhibits. The document is short (2621 characters) and primarily serves as an announcement of these materials rather than containing detailed financial data or the reports themselves. It does not contain financial statements or detailed analysis, nor is it a transcript or a regulatory certification. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2017-01-20 English
FORM 4 SUBMISSION
Director's Dealing
2017-01-13 English
FORM 8-K
Investor Presentation Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce significant events. The key content is the attachment of an investor presentation dated January 2017, which the company states it may use in conversations with investors and analysts. The document itself is short (2440 characters) and primarily serves to file the investor presentation as an exhibit. There are no financial statements or detailed financial analysis within the text, only a reference to the investor presentation. According to the classification rules, an investor presentation attached as an exhibit to a Form 8-K should be classified as an Investor Presentation (IP).
2017-01-06 English
FORM 4 SUBMISSION
Director's Dealing
2017-01-06 English
FORM 4 SUBMISSION
Director's Dealing
2017-01-05 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.